Sareen Habeshian,April

Sareen Habeshian is a breaking news reporter on the Newsdesk. She can be reached at sareen.habeshian@axios.com. Her primary topics of coverage include health, world events, and politics and policy.

Biography:  https://www.axios.com/authors/shabeshian

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

100%

Examples:

No current examples available.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

Supreme Court Upholds FDA Approval of Abortion Pill Mifepristone, Preserving Access for Now

Supreme Court Upholds FDA Approval of Abortion Pill Mifepristone, Preserving Access for Now

Broke On: Thursday, 13 June 2024 The Supreme Court unanimously upheld the FDA's approval of mifepristone, preserving nationwide access to the abortion pill. The ruling sets a precedent against judges limiting patient access to critical medications and politicizing the FDA's approval process. Mifepristone, a safe and effective drug used in combination with misoprostol for medication abortions, remains crucial for many people in states with limited clinic access. Challenges to reproductive health care continue as anti-abortion groups seek further restrictions.